4 completed. 4 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
| Phase 1 | 3 | Completed 3 |
Follow XL147: new trials by email Literature Review of XL147 trials Research Report on XL147
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen SAR245408, SAR245409 - Neoplasm Malignant | Phase 1 / Phase 2 | Completed | Sanofi | 61 | 2012-07-20 | 2022-04-19 |
| Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer XL147 (SAR245408), XL765 (SAR245409), letrozole (Femara) - Breast Cancer | Phase 1 / Phase 2 | Completed | Sanofi | 72 | 2010-06-01 | 2016-06-03 |
| Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen XL147 (SAR245408), trastuzumab, paclitaxel - Breast Cancer, Breast Neoplasms | Phase 1 / Phase 2 | Completed | Sanofi | 42 | 2010-02-01 | 2016-06-03 |
| Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma XL147 (SAR245408) - Endometrial Cancer, Endometrial Neoplasms | Phase 2 | Completed | Sanofi | 67 | 2010-01-01 | 2016-06-03 |
Breast Neoplasms (2) · Endometrial Neoplasms (1) · Neoplasms (1)
Sanofi (4)
United States (4) · Spain (3) · Belgium (2) · France (2)